Antibodies to watch in 2024

The ‘Antibodies to Watch’ series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this webinar, we discuss key details for antibody therapeutics granted a first approval in 2023. We briefly review product candidates for which marketing applications are under consideration in at least one country or region, and investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These product candidates include numerous innovative bispecific antibodies and antibody-drug conjugates. We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutics development efforts by the biopharmaceutical industry are robust and increasingly successful.
About the speakers:
Dr. Silvia Crescioli is a Consultant for The Antibody Society and chair of The Antibody Society Communication and Membership Committee. Since 2021 she has co-authored the “Antibodies to watch” articles in published in mAbs, reviewing recently approved antibody therapeutics, and forecasting antibody therapeutics marketing application submission as well as approvals that might occur the following year. Dr. Crescioli received her PhD in Biomedical Sciences, Experimental Oncology, from the University of Florence in 2014, followed by eight years as a post doc at King’s College London in Prof. Karagiannis’ Cancer Antibody Discovery & Immunotherapy Group, where she is now a visiting Research Fellow. Her research interests focus on antibody therapeutics development for both cancer and noncancer indications, as well as on different areas of cancer immunology and immunotherapy, including antibody discovery, antibody engineering and glycoengineering.
Dr. Janice Reichert, Chief Operating Officer of The Antibody Society, is an internationally-recognized expert in the development of antibody therapeutics. She is Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. She received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.